-
June 17, 2022 Psychedelic Business Spotlight – June 17This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin...
-
June 16, 2022 The Four Psychedelics ETFs Capturing Investor AttentionDespite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and...
-
May 19, 2022 Psychedelic Capitalism Takes a Trip to DavosFrom May 21-26, for the first time, the Davos Forum will feature The House of...
-
May 17, 2022 Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisOur resident psychedelic investor explains a handful of important metrics to study when analyzing and...
-
May 11, 2022 MindMed’s Phase 2 LSD Trial Treating Anxiety Was a SuccessResearchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
-
May 6, 2022 Wesana Health May Sell Clinics to Focus Solely on Drug Development: An AnalysisWesana Health reaches a major strategic pivot point. Our resident Psychedelic Investor examines what this...
-
May 2, 2022 Elon Musk Excites Psychedelic Industry CEOs with This TweetThis is one of the billionaire's most explicit acknowledgments of the power of psychedelics for...
-
April 29, 2022 Why Field Trip Health Is Dividing in Two — and What This Means for InvestorsField Trip Health plans to split into two independent, publicly traded companies: Field Trip Health...
-
April 21, 2022 Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial...
-
April 12, 2022 Numinus Acquiring Novamind in First Major Psychedelics MergerThis deal will make Numinus the psychedelic medicines company with the highest revenue, though of...
